In short
Clinical trials of Amitriptyline are studying how it performs in different pain conditions, especially neuropathic pain and chronic back pain. These studies look at pain relief, tolerability, and how it compares with other treatments or placebo in adults with ongoing pain.
Key points
- Clinical trials of Amitriptyline in the provided data focus on pain conditions, especially neuropathic pain and chronic back pain. The studies include one Phase 2 trial and several Phase 3 trials, all completed. Target groups include people with head and neck cancer in remission, diabetic polyneuropathy, traumatic or post-operative peripheral neuropathy, chronic back pain, and central neuropathy. The main goal is to see whether pain scores improve over time. Some trials compare Amitriptyline with placebo or with other treatment approaches. One study also measures how many patients achieve at least a 2-point drop in average pain.
Trial overview
The provided trials investigate Amitriptyline in studies of pain, mainly neuropathic pain, which means pain caused by nerve problems. These studies are not about the drug as a general medicine; they focus on how it is used in research for specific pain conditions.
All five trials in the source data are marked Completed. They include one Phase 2 study and four Phase 3 studies.
Conditions studied
The trials cover several long-lasting pain conditions. One study looks at people with head and neck cancer in remission who still have neuropathic pain.
Other studies focus on chronic pain due to traumatic or post-operative peripheral neuropathy, chronic back pain, diabetic polyneuropathy, and central neuropathy of any genesis. “Any genesis” means the cause can be any origin, not just one single cause.
Study designs and phases
All trials are interventional, which means the researchers give a treatment and then measure what happens. The Phase 2 study has 130 planned participants, while each Phase 3 study has 558 planned participants.
Phase 2 studies usually explore whether a treatment may help and continue safety checks. Phase 3 studies are larger and are used to compare treatments more clearly.
Main outcomes measured
The main outcome in most trials is pain change, measured with the Numeric Rating Scale (NRS), a 0 to 10 pain score where higher numbers mean more pain. These studies compare pain at the start of the trial with pain after treatment, including week 14 in the Phase 3 studies.
In the Phase 2 head and neck cancer study, the main outcome is the rate of patients whose average pain over the last 24 hours drops by 2 points at 9 months compared with entry into the study. This is a way to measure a meaningful improvement in pain for the patient.
Who participated
The target populations are adults with chronic pain related to nerve injury or nerve disease, and one group with cancer-related neuropathic pain after remission. The trial data do not provide full entry rules, so the exact inclusion and exclusion criteria are not shown here.
What the trials compare
Several studies compare Amitriptyline-related treatment approaches with placebo, which is a look-alike treatment without active medicine. The head and neck cancer study compares a capsaicin patch strategy with a reference neuropathic treatment using Amitriptyline.
The Phase 3 studies also list other pain treatments in their intervention sets, showing that the research is part of broader comparisons for chronic pain management. The source data name AP707 in several trials, which is the study treatment being evaluated in those trials.